Persson Egon, Foscolo Tina, Hansen Martin
Haemophilia Research Novo Nordisk A/S Måløv Denmark.
Res Pract Thromb Haemost. 2018 Dec 7;3(1):114-120. doi: 10.1002/rth2.12167. eCollection 2019 Jan.
Factor VIII (FVIII) procoagulant activity is commonly assessed by measuring the activated partial thromboplastin time (APTT) to clot formation using one of the many available but differently composed reagents. The majority of APTT reagents also accurately recover the activity of the extended half-life molecule N-glycoPEGylated FVIII (N8-GP; turoctocog alfa pegol), while a few silica-based reagents give a low recovery.
To identify the cause of N8-GP activity underestimation in the presence of certain silica-based APTT reagents.
Development of FVIIIa-dependent tenase activity and appearance of FVIIIa from N8-GP and its non-PEGylated counterpart (N8) were compared using clotting assays, a factor Xa (FXa) activity assay mimic thereof, and thrombin activation time courses.
A trong correlation was demonstrated between clotting and FXa activity assays based on similar recoveries of N8-GP activity and equal responses to an altered duration of the contact activation phase, validating the latter as a useful clotting assay mimic. Contact activation phase duration influenced, and could even eliminate, N8-GP activity underestimation. Thrombin-catalyzed conversion of N8-GP to FVIIIa was considerably slower than that of N8 despite similar extents of adsorption to silica particles in APTT-SP, suggesting different modes and/or orientations of adsorption.
Some contact activators reduce thrombin's ability to cleave N8-GP more than native FVIII. Decelerated thrombin activation of N8-GP is reflected in delayed FVIIIa-dependent appearance of FXa activity in plasma, in turn leading to prolonged clotting time. This forms the basis for underestimation of N8-GP activity as measured by one-stage clotting assay against a FVIII standard.
凝血因子VIII(FVIII)的促凝血活性通常通过使用多种成分不同但均可获得的试剂之一来测量活化部分凝血活酶时间(APTT)至血凝块形成来评估。大多数APTT试剂也能准确恢复延长半衰期分子N-糖基聚乙二醇化FVIII(N8-GP;聚乙二醇化重组人凝血因子VIII)的活性,而少数基于二氧化硅的试剂回收率较低。
确定在某些基于二氧化硅的APTT试剂存在下N8-GP活性被低估的原因。
使用凝血试验、模拟其的因子Xa(FXa)活性试验以及凝血酶激活时间过程,比较了N8-GP及其非聚乙二醇化对应物(N8)的FVIIIa依赖性凝血酶原酶活性的发展和FVIIIa的出现情况。
基于N8-GP活性的相似回收率以及对接触激活阶段持续时间改变的相同反应,凝血试验和FXa活性试验之间显示出强烈的相关性,证实后者是一种有用的凝血试验模拟方法。接触激活阶段的持续时间影响甚至可以消除N8-GP活性的低估。尽管在APTT-SP中N8-GP和N8对二氧化硅颗粒的吸附程度相似,但凝血酶催化N8-GP转化为FVIIIa的速度明显慢于N8,这表明吸附模式和/或方向不同。
一些接触激活剂对凝血酶切割N8-GP的能力的降低程度超过了对天然FVIII的影响。N8-GP的凝血酶激活延迟反映在血浆中FVIIIa依赖性FXa活性出现延迟,进而导致凝血时间延长。这构成了在针对FVIII标准的单阶段凝血试验中N8-GP活性被低估的基础。